Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2020

View Archived Issues

FDA clears IND for phase I/IIa study of V2ACT for pancreatic cancer

Graphite Bio allowed to initiate phase I/II CEDAR study of GPH-101 in sickle cell disease

Updated results from phase I/II study of FLT-180a in hemophilia B

Paying attention to the little guy in proteomics

Gene therapy in one eye improves vision in both

Codagenix announces the initiation of first in human study of COVI-VAC in the U.K.

Cancer Research UK approves Teon's TT-702 for clinical collaboration

Ashvattha collaborates with Stanford on preclinical study of OP-801 imaging of neuroinflammation

Positive interim data presented from phase IIb portion of ifenprodil COVID Study

First phase III study of dasiglucagon in congenital hyperinsulinism does not meet primary endpoint

Verastem initiates phase II registration-directed study of VS-6766 plus defactinib in NSCLC

Lantern announces promising preclinical data for LP-184 in GBM

Positive phase II data for PL-9643 in patients with moderate to severe dry eye disease

Initiation of first-in-human study of CVB vaccine candidate, PRV-101

Phase I results show safety and activity with rintodestrant in ER+/HER2- breast cancer

Voronoi discloses new RET inhibitors

First patients enrolled in phase IIb study of rNAPc2 for COVID-19

Merck & Co. patents NPR1 agonists

Medshine Discovery identifies new RIP-1 inhibitors

Merck & Co. discovers new compounds for HIV infection

SMAD3 as new therapeutic target for NSCLC

Duke University presents new pro-N-cadherin-targeting humanized antibodies

PRDM2, a novel SMAD3-dependent immunosuppressor for promoting NSCLC

Phase IIb/III study of oral masitinib in Alzheimer's disease meets primary endpoint

Low-dose cohort data reported from phase I/II study of AXO-AAV-GM1 for GM1 gangliosidosis

Glutamate "plumes" identified in spreading depression, migraine

Valneva opens phase I/II study of COVID-19 vaccine candidate VLA-2001

Clinical benefit seen with SOR-007 in patients with cutaneous metastases

Nascent cleared by FDA to begin phase I trial of pritumumab for brain cancer

Kineta initiates phase I trial of KCP-506 for chronic neuropathic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...